Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The therapeutic management of antibody-mediated autoimmune disease typically involves immunosuppressant and immunomodulatory strategies. However, perturbing the fundamental role of the neonatal Fc receptor (FcRn) in salvaging IgG from lysosomal degradation provides a novel approach - depleting the body of pathogenic immunoglobulin by preventing IgG binding to FcRn and thereby increasing the rate of IgG catabolism. Herein, we describe the discovery and preclinical evaluation of fully human monoclonal IgG antibody inhibitors of FcRn. Using phage display, we identified several potent inhibitors of human-FcRn in which binding to FcRn is pH-independent, with over 1000-fold higher affinity for human-FcRn than human IgG-Fc at pH 7.4. FcRn antagonism in vivo using a human-FcRn knock-in transgenic mouse model caused enhanced catabolism of exogenously administered human IgG. In non-human primates, we observed reductions in endogenous circulating IgG of >60% with no changes in albumin, IgM, or IgA. FcRn antagonism did not disrupt the ability of non-human primates to mount IgM/IgG primary and secondary immune responses. Interestingly, the therapeutic anti-FcRn antibodies had a short serum half-life but caused a prolonged reduction in IgG levels. This may be explained by the high affinity of the antibodies to FcRn at both acidic and neutral pH. These results provide important preclinical proof of concept data in support of FcRn antagonism as a novel approach to the treatment of antibody-mediated autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407
Is increased blinking a form of blepharospasm?
(2013) · CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) · doi:10.1212/wnl · Cited by 355
Raghavan, M., Bonagura, V. R., Morrison, S. L., & Bjorkman, P. J. (1995) · Biochemistry · doi:10.1021/bi00045a005 · Cited by 317
Albumin Binding to FcRn: Distinct from the FcRn−IgG Interaction
Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M., & Anderson, C. L. (2006) · Biochemistry · doi:10.1021/bi052628y · Cited by 290
Montoyo, H. P., Vaccaro, C., Hafner, M., Ober, R. J., Mueller, W., & Ward, E. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810796106 · Cited by 211
Cited by
Howard, J. F., Bril, V., Vu, T., Karam, C., Peric, S., Margania, T., Murai, H., Bilinska, M., Shakarishvili, R., Smilowski, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00159-9 · Cited by 739
The Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 429
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Ulrichts, P., Guglietta, A., Dreier, T., van Bragt, T., Hanssens, V., Hofman, E., Vankerckhoven, B., Verheesen, P., Ongenae, N., Lykhopiy, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97911 · Cited by 427
The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
Kiessling, P., Lledo-Garcia, R., Watanabe, S., Langdon, G., Tran, D., Bari, M., Christodoulou, L., Jones, E., Price, G., Smith, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan1208 · Cited by 211
Smith, B., Kiessling, A., Lledo-Garcia, R., Dixon, K. L., Christodoulou, L., Catley, M. C., Atherfold, P., D’Hooghe, L. E., Finney, H., Greenslade, K., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1505464 · Cited by 117
Metadata
- Authors
- Nixon, A. E., Chen, J., Sexton, D. J., Muruganandam, A., Bitonti, A. J., Dumont, J., Viswanathan, M., Martik, D., Wassaf, D., Mezo, A., Wood, C. R., Biedenkapp, J. C., & TenHoor, C.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2015-04-23
- Volume
- 6
- Pages
- 176-176
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2008895923
- Cited by
- 66
- References
- 7
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates. https://app.cochat.ai/papers/10.3389/fimmu.2015.00176
- The paper
- Nixon, A. E., Chen, J., Sexton, D. J., Muruganandam, A., Bitonti, A. J., Dumont, J., Viswanathan, M., Martik, D., Wassaf, D., Mezo, A., Wood, C. R., Biedenkapp, J. C., & TenHoor, C. (2015). Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2015.00176
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.